...
首页> 外文期刊>Gynecologic Oncology: An International Journal >Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin
【24h】

Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin

机译:血清人附睾蛋白4(HE4)作为区分上皮性卵巢癌和胃肠源性卵巢转移的生物标志物

获取原文
获取原文并翻译 | 示例

摘要

Objective. About 5-15% of all malignant ovarian tumors are metastases from other malignancies such as gastrointestinal tumors, breast cancer or melanoma. Also other gynecological tumors can metastasize to the ovaries. It is crucial to differentiate between primary epithelial ovarian cancer (EOC) and ovarian metastases because different treatment is required. The clinical value of human epididymal secretory protein 4 (HE4) as a serum biomarker in primary ovarian cancer has been established. The use of HE4 in the differentiation between primary ovarian cancer and ovarian metastases from other malignancies has never been investigated.
机译:目的。所有恶性卵巢肿瘤中约有5-15%来自其他恶性肿瘤的转移,例如胃肠道肿瘤,乳腺癌或黑色素瘤。其他妇科肿瘤也可转移至卵巢。区分原发性上皮性卵巢癌(EOC)和卵巢转移至关重要,因为需要不同的治疗方法。已经确定了人类附睾分泌蛋白4(HE4)作为原发性卵巢癌中血清生物标志物的临床价值。从未研究过将HE4用于区分原发性卵巢癌和其他恶性肿瘤的卵巢转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号